Takis is a start up Biotechnology Company based in Rome, Italy. Our group has more than 10 years of experience in drug discovery; we have contributed to the validation of new targets for the treatment of chronic viral diseases and cancer and to a number of IND/CSA filings in the areas of virology and oncology. Our team is also recognized for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity.
Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.
Takis plans to bring its core vaccine candidates through Phase I and Phase II proof-of-concept trials.